Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran
Authors:
- Ellis F. UngerEUEllis F. Unger
- Robert TempleRTRobert Temple
Open Access
- 12 May 2011
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 364 (19) , 1788-1790
Abstract
On October 19, 2010, the Food and Drug Administration (FDA) approved dabigatran for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Approval was based on a multicenter, active-control trial, the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY),1 in which patients were randomly assigned to receive 150 mg of dabigatran, 110 mg of dabigatran, or warfarin. Dabigatran was given twice daily; warfarin was titrated to achieve an international normalized ratio (INR) of 2.0 to 3.0. Assignment to warfarin or dabigatran treatment was unblinded; assignment to a specific dabigatran dose was double-blind. RE-LY was a noninferiority study, attempting to rule out a hazard ratio of more than 1.38 for the primary end point, stroke or systemic embolism.2Keywords
This publication has 2 references indexed in Scilit:
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial FibrillationStroke, 2006